Underestimation Rate in the Percutaneous Diagnosis of Radial Scar/Complex Sclerosing Lesion of the Breast: Systematic Review

Taxa de subestimação no diagnóstico percutâneo de cicatriz radiada/lesão esclerosante complexa da mama: Revisão sistemática

Ana Beatrice Bonganha Zanon1© Jonathan Yugo Maesaka2© Bruna Bello Chequin2© Ana Gabriela de Siqueira Santos2© Edmund Chada Baracat1,2© José Roberto Filassi1,2©

1 Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil
2 Divisão de Ginecologia, Setor de Mastologia, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

Address for correspondence Jonathan Yugo Maesaka, MD, Av. Dr. Enéas de Carvalho Aguiar, 255, 10o andar, São Paulo, SP, Brazil (e-mail: jonathan.maesaka@hc.fm.usp.br).

Rev Bras Ginecol Obstet 2022;44(1):67–73.

Abstract

Objective To evaluate the underestimation rate in breast surgical biopsy after the diagnosis of radial scar/complex sclerosing lesion through percutaneous biopsy.

Data Sources A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. The PubMed, SciELO, Cochrane, and Embase databases were consulted, with searches conducted through November 2020, using specific keywords (radial scar OR complex sclerosing lesion, breast cancer, anatomopathological percutaneous biopsy AND/OR surgical biopsy).

Data collection Study selection was conducted by two researchers experienced in preparing systematic reviews. The eight selected articles were fully read, and a comparative analysis was performed.

Study selection A total of 584 studies was extracted, 8 of which were selected. One of them included women who had undergone a percutaneous biopsy with a histological diagnosis of radial scar/complex sclerosing lesion and subsequently underwent surgical excision; the results were used to assess the underestimation rate of atypical and malignant lesions.

Data synthesis The overall underestimation rate in the 8 studies ranged from 1.3 to 40% and the invasive lesion underestimation rate varied from 0 to 10.5%.

Conclusion The histopathological diagnosis of a radial scar/complex sclerosing lesion on the breast is not definitive, and it may underestimate atypical and malignant lesions,
which require a different treatment, making surgical excision an important step in diagnostic evaluation.

**Introduction**

Radial scar/complex sclerosing lesion (RS/CSL) is a benign breast disease, characterized macroscopically by an architectural distortion of the breast tissue with radial spikes in the center and, microscopically, by a central area of fibroblastosis from which ducts and lobes radiate. The distinction between both nomenclatures is based only on the size of the lesion: the radial scar measures < 1 cm and the complex sclerosing lesion is > 1 cm. Most are microscopic, multiple, bilateral, and not palpable on clinical examination.

The implementation of screening programs and the consequent increase in the number of asymptomatic patients undergoing mammography contributed to a 3-fold increase in the detection of these lesions in percutaneous biopsies. Due to its radiological and histological similarity to invasive cancer and its association with other atypical lesions, RS/CSL arouses the interest of researchers; however, the real need for surgical excision is questioned in view of a histopathological diagnosis enabled by percutaneous biopsy. Once a histological diagnosis is reached after a percutaneous biopsy, the potential for intrinsic malignancy of the lesion must be considered. The lesion can develop into atypical proliferations, including atypical hyperplasia and invasive carcinoma. Besides, its coexistence with cancer and other high-risk lesions should be taken into account.

**Methods**

We conducted a systematic review for the assessment of the underestimation degree of malignant lesions based on a histological diagnosis of RS/CSL lesion after surgical excision and percutaneous biopsy. Studies evaluating RS/CSL with atypia by means of percutaneous biopsy were not included. The review followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) guidelines (Fig. 1). The recommendations were adapted from observational studies given the lack of clinical trials.

Pubmed/Medline: radial scar [All Fields] OR complex sclerosing lesions [All Fields] AND (breast neoplasms [MeSH Terms] OR [All Fields] AND neoplasms [All Fields]) OR breast neoplasms [All Fields] OR (breast [All Fields] AND cancer [All Fields]) OR breast cancer [All Fields]) AND (pathology [Subheading] OR pathology [All Fields] OR biopsy [All Fields] OR biopsy [MeSH Terms]). Scielo: radial scar. Cochrane: radial scar. Embase: (radial scar/exp OR radial scar OR complex sclerosing lesions AND (breast cancer/exp OR breast cancer OR [breast/exp OR breast] AND (cancer/exp OR cancer))) AND (biopsy/exp OR biopsy). Article search and selection were conducted by two researchers experienced in preparing systematic reviews (Zanon A. B. B. and Maesaka J. Y.), with searches conducted through November 2020. Discrepancies in the selection of articles by these researchers were solved through group discussion with the participation of a third researcher (Chequin B. B.).

Results

The process of searching, identifying, and selecting articles is in Fig. 1. From a total of 584 articles, 8 studies were selected for inclusion in the final analysis. The main reasons for exclusion were the following: studies unrelated to the main objective of our review (female patients who underwent biopsy with a resultant histological diagnosis of RS/CSL and subsequently underwent surgical excision, enabling assessment of the underestimation degree of atypical and malignant lesions), type of studies (original studies only), duplicate articles, and articles not written in English or Portuguese. The 8 studies included 630 cases of RS/CSL on percutaneous biopsy, 442 of which subsequently underwent surgical excision (Table 1). The mean age of the patients was 54.8 years old. There were 425 patients who underwent biopsies; of these, 95 (22%) were found to have RS/CSL on core needle biopsy and 77 had radial scar without evidence of atypia. Analysis of these 77 patients showed that the upgrade to the atypia rate was 31% (24 of 77) and to the carcinoma in situ rate was 9% (7/77). There was no upgrade to invasive carcinoma. Therefore, the overall underestimation rate was 40%.

In Woodward et al., a retrospective review using a single institutional pathology and radiology database was conducted for all radial scars identified on core biopsy from January 2010 to January 2017. The mean age of the patients with benign biopsies was 52.9 years old. Sixty-six isolated RSs were identified and 44 underwent surgical excision. Fifteen upgraded to atypical lesions (flat epithelial hyperplasia [6], atypical ductal hyperplasia [5], lobular carcinoma in situ [2], atypical lobular hyperplasia [1], and atypical ductal hyperplasia/lobular hyperplasia [1]) and 2 upgraded to malignancy (ductal carcinoma in situ [1] and invasive ductal carcinoma [1]). The overall underestimation rate was 38% and the invasive lesion underestimation rate was 2.2%.

Gašić et al. in a retrospective study using a database from the Slovenian National Breast Cancer Screening Program, checked all patients with a radial scar or a complex sclerosing lesion who underwent core needle biopsy between 2008 and 2018. The mean age was 61.5 years old. Of the 156 patients selected, 107 (68.6%) had radial scars or complex sclerosing lesions without atypia, and 76 of these patients underwent surgical excision. Seventy-five patients had nonmalignant lesions (atypical proliferative lesions, lobular neoplasia, and papilloma) on final excision and no patient had carcinoma...
ductal in situ only. One case was upgraded to invasive carcinoma. The overall underestimation rate was 1.3%.

Bacci et al. retrieved from an electronic medical record every patient with a histological diagnosis of RS/CSL through vacuum-assisted biopsy at the Comprehensive Cancer Care Centre – Institut Bergonie (France) over a period of 7 years and 5 months, from May 2008 to October 2015. The mean age was 53.4 years old (range: 25 to 83 years old). Ninety-two

### Table 1: Study selection

| Author, year of publication | Type of study | RS/CSL diagnosed after percutaneous biopsy | Mean age (years old) (range) | RS/CSL that underwent surgical excision |
|-----------------------------|---------------|------------------------------------------|------------------------------|---------------------------------------|
| Quinn et al. (2020)         | Retrospective | 77                                       | 54.8 (50–64)                | 77                                    |
| Woodward et al. (2020)      | Retrospective | 66                                       | 55.6 (19–76)                | 44                                    |
| Gašljević et al. (2020)     | Retrospective | 107                                      | 61.5 (50–69)                | 76                                    |
| Bacci et al. (2019)         | Retrospective | 92                                       | 53.4 (25–83)                | 48                                    |
| Mooney et al. (2016)        | Retrospective | 54                                       | 53.2                         | 25 (46%)                              |
| Matrai et al. (2015)        | Retrospective | 77                                       | 51.4 (37–79)                | 77 (100%)                             |
| Nassar et al. (2015)        | Retrospective | 100                                      | 50.2 (23–74)                | 38 (38%)                              |
| Stefenon et al. (2003)      | Retrospective | 57                                       | 49 (31–84)                  | 57 (100%)                             |
| Final conclusion            | –             | 630                                      | 54                           | 442                                   |

Abbreviation: RS/CSL, radial scar/complex sclerosing lesion.

### Table 2: Diagnosis after surgical excision

| Author, year of publication | Atypia and LCIS | DCIS | Invasive carcinoma | Overall underestimation rate |
|-----------------------------|-----------------|-----|--------------------|-----------------------------|
| Quinn et al. (2020)         | 24/77 (31%)     | 7/77 (9%) | 0/77 (0%)            | 31/77 (40%)                |
| Woodward et al. (2020)      | 15/44 (34%)     | 1/44 (2.2%) | 1/44 (2.2%)          | 17/44 (38%)                |
| Gašljević et al. (2020)     | 0/76 (0%)       | 0/76 (0%) | 1/76 (1.3%)          | 1/76 (1.3%)                |
| Bacci et al. (2019)         | 16/48 (33.3%)   | 0/48 (0%) | 0/48 (0%)            | 16/40 (33.3%)              |
| Mooney et al. (2016)        | 5/25 (20%)      | 3/25 (12%) | 1/25 (4%)            | 11/25 (36%)               |
| Matrai et al. (2015)        | 9/77 (11.7%)    | 0/77 (0%) | 0/77 (0%)            | 9/77 (11.7%)               |
| Nassar et al. (2015)        | 7/38 (18.4%)    | 2/38 (5.3%) | 2/38 (5.3%)          | 11/38 (28.9%)             |
| Stefenon et al. (2003)      | 9/57 (15.8%)    | 0/57 (0%) | 6/57 (10.5%)         | 15/57 (26.3%)             |
| Final conclusion            | 85/442 (19.2%)  | 13/442 (2.9%) | 11/442 (2.4%)        | 109/442 (24.6%)           |

Abbreviations: ADH, atypical ductal hyperplasia; ALH, atypical lobular hyperplasia; DCIS, ductal carcinoma in situ; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ; FEA, flat epithelial hyperplasia; RSA, radial scar with atypia.

Quinn et al. performed a retrospective review of articles retrieved from a breast screening database at one of the four national units in Ireland. Patients with a radial scar identified on core biopsy or surgical excision were selected.Radial scars without atypia (on core or excision biopsy) were analyzed separately from those with any coexistent risk lesions.
benign biopsies were identified (biopsies showing isolated RS/CSL or RS/CSL associated with other proliferative lesions without atypia), and 48 lesions underwent surgical excision. After surgery, 16 upgraded to atypia (flat epithelial hyperplasia in 16.7% [8], atypical ductal hyperplasia in 12.5% [6], and atypical lobular hyperplasia in 12.5% [6]). Not a single benign biopsy upgraded to carcinoma in situ or to invasive carcinoma. The overall underestimation rate was 33.3%.

Mooney et al.,\textsuperscript{10} in a retrospective review spanning 14.5 years in Los Angeles (USA), analyzed 5,750 results of core biopsy (the needle size was not specified): 462 were high-risk lesions and 54 were radial scars. Of the latter cases, 25 (46%) underwent surgical excision. Of the remaining 29 cases, 12 did not undergo surgical excision due to loss to follow-up, and 17 had documentation recommending radiological follow-up for 6 months. Surgical excision revealed 5 atypical lesions (atypical ductal hyperplasia [2], atypical lobular hyperplasia [2], and radial scar with atypia [1]), 3 ductal carcinomas in situ, and 1 invasive lobular carcinoma. The general underestimation rate was 36%, while the invasive lesion underestimation rate was 4%. Of the high-risk lesions analyzed, the radial scars were less associated with malignant lesions after excision than atypical ductal hyperplasia (odds ratio [OR] = 0.29; \( p = 0.014 \); confidence interval [CI] = 0.11–0.77, in this cited study, the range was not mentioned). In addition, in the benign results, the number of cases with Breast Imaging Reporting and Data System (BIRADS) \( < 4B \), nodules \( < 1 \) cm, and absence of calcifications was lower than that in the malignant results after surgical excision.\textsuperscript{10}

In Matrai et al.,\textsuperscript{11} 77 radial scar lesions were found in core biopsies, which subsequently underwent surgical excision were identified in New York (USA). Three patients (3/77) were upgraded to atypical lesions (atypical ductal hyperplasia [2] and atypical lobular hyperplasia [1]) and 6 to lobular carcinoma in situ. There was no upgrade to ductal carcinoma in situ or to invasive carcinoma. The overall underestimation rate was 11.7%. Older age was a predictor of higher risk of upgrade in this setting (62.0 versus 49.9 years old, \( p < 0.001 \)).\textsuperscript{11}

Nassar et al.\textsuperscript{12} performed a retrospective chart review of cases of RS/CSL diagnosed by core biopsy from January 1, 1994 to August 31, 2013 in a single institution in Rochester (USA). One hundred RS/CSL were identified, and the mean age of the patients was 50.2 years old. Of the 100 lesions, 38 underwent surgical excision. The median size of the excision was 1.2 cm (69% > 1 cm). The results were the following: 6 atypical lesions (atypical ductal hyperplasia [1] and atypical lobular hyperplasia [5]), 1 lobular carcinoma in situ, 2 ductal carcinomas in situ, and 2 invasive carcinomas, with an overall underestimation rate of 28.9% and an invasive lesion underestimation rate of 5.3%.\textsuperscript{12} Of these 11 lesions, all were diagnosed with radial scar: 3 by mammotomy and 8 by core biopsy.

Stefanon et al.\textsuperscript{1} reviewed cases from the archives of the Diagnostic Imaging Center and of the Hospital Santa Rita, Vitória, state of Espírito Santo, Brazil, between October 1993 and December 2001. Of the 926 lesions that underwent percutaneous biopsy, 57 were histopathologically diagnosed with RS/CSL. The mean age of the patients was 49 years old (range: 31 to 84 years old). The lesions were palpable in 10 cases. Mammography showed 48 cases of distortion in architecture, 4 of spiculated nodule, 4 of asymmetric density, and 14 of microcalcifications. The diagnosis after surgical excision was 9 atypical lesions (atypical ductal hyperplasia [5] and atypical lobular hyperplasia [4]), 3 ductal carcinomas in situ together with tubular carcinoma (without specification of adjacent or distant location), 2 tubular carcinomas, and 1 invasive carcinoma. The overall underestimation rate was 26.3% and the invasive lesion rate was 1.7%.\textsuperscript{1}

**Discussion**

The behavior of RS/CSL, a benign lesion of the breast, is not well known, owing to its mimicry and possible progression to atypia and cancer.\textsuperscript{12} However, complex sclerosing lesion should not be confused with sclerosing adenosis. The latter refers to another type of benign lesion of glandular proliferation.

Many studies have questioned the need for surgical excision since a histopathological diagnosis is also enabled percutaneously. Brenner et al.\textsuperscript{2} in 2002, propounded that percutaneous biopsy should only be complemented by surgical excision when there is associated atypical hyperplasia, a biopsy with < 12 fragments, or when mammographic findings are not compatible with the histological diagnosis of RS/CSL.\textsuperscript{2} Chou et al.,\textsuperscript{13} in 2018, in a follow-up of a mean of 32.3 months, found that in only 1.6% of the patients with a percutaneous diagnosis of RS, the disease had developed into invasive carcinoma. Thus, the RS on percutaneous biopsy could be followed-up with clinical monitoring without the need for an excisional biopsy.\textsuperscript{13}

Similarly, Nassar et al.,\textsuperscript{12} in 2015, suggested that RS size at image and the biopsy tissue volume sample may be related to the likelihood of underestimation. Of 11 cases upstaged at excision, 8 (73%) of them were not vacuum-assisted. In this study, “upstaging was noted more often in women with RS lesions larger than 1.0cm and in women with worrisome radiologic features.” In this data, the 29% overall underestimation rate supported the role of excisional biopsy in the follow-up of patients with RS/CSL on percutaneous biopsy.\textsuperscript{12}

Reaching a correct diagnosis is of extreme clinical importance since the postsurgical treatment described in the literature is different for each lesion. The pure RS/CSL requires no additional procedures. In high-risk histological lesions, an association with endocrine therapy is recommended. For these high-risk lesions, the use of tamoxifen (selective estrogen receptor modulator [SERM]) reduces the risk of invasive carcinoma by 49% (\( p < 0.0001 \)) and of carcinoma in situ by 50% (\( p < 0.002 \)). Likewise, the use of aromatase inhibitors demonstrated a 49% decrease in the risk of breast cancer (HR = 0.51; CI = 0.39–0.66; \( p < 0.0001 \)).\textsuperscript{14,15} In ductal carcinoma in situ, radiotherapy, after conservative surgery with free margins, reduces the risk of recurrence by up to 59% (HR = 0.41; CI = 0.30–0.57; \( p < 0.0001 \)) and the association with tamoxifen for 5 years also contributes significantly to this reduction (HR = 0.71;
CI = 0.58–0.88; p = 0.002).16,17 Finally, invasive carcinomas may require adjuvant treatment (radiotherapy or systemic treatment), depending on histological type, molecular subtype, and staging.

The present study showed that a significant portion of percutaneous biopsies with a diagnosis of RS/CSL turned out to be atypical and malignant lesions upon examination after surgical excision, with a general underestimation rate ranging from 1.3 to 40% in the review studies. In 5 of the 8 studies analyzed, the diagnosis of invasive carcinoma after excision was made, so that the invasive lesion underestimation rate ranged from 1.3 to 10.5% in the studies.

The small number of published articles and their statistical variation constitute a limitation of the present study. The variance may be explained by a different patient profile at each center. The similarity in the mean age of the patients in the 8 studies is stated, but there is no mention of the comorbidities of the patients and of the period between percutaneous and surgical biopsies. There is much variability of percutaneous biopsy types performed in each study: some of the diagnoses were obtained by vacuum-assisted biopsies and others by core biopsies, and two studies did not specify needle sizes, nor the methods used. Probably, a vacuum-assisted biopsy should have a lower underestimation rate than a core biopsy, because it yields larger tissue samples. Despite these limitations and considering that, of the 442 RS/CSL which underwent surgical excision, 109 upgraded to atypical and malignant lesions, which amounts to a 24.6% rate, the present review presents relevant data and reinforces the assumption that a diagnosis by percutaneous biopsy alone can underestimate atypical and malignant lesions.

The relatively high underestimation rate shows the fundamental role of surgical excision in the confirmation of a diagnosis, which is necessary to define an appropriate treatment plan for each patient.

Conclusion

The histopathologic diagnosis of a RS/CSL by percutaneous biopsy is not definitive and may underestimate atypical and malignant lesions, as pointed out in the reviewed studies. In the management of RS/CSL diagnosed by percutaneous biopsy, it is important to consider the volume of tissue evaluated. The high underestimation rate identified in the present study shows the role of surgical excision in the management of the patient.

Conflict of interests
The authors have no conflict of interests to declare.

Acknowledgments
The present review is dedicated to the memory of Prof. Nestor de Barros, MD, a model of excellence in breast radiology in Brazil and responsible for the training of many specialists.

References

1. Stefeno CC, Carvalho AA, Djahjah MC, Koch HA. Cicatriz radial/lesão esclerosante complexa: aspectos radiológicos com correlação clínica, ultra-sonográfica e anatomo-patológica. Radiol Bras. 2003;36(02):95–103. Doi: 10.1590/S0100-39842003000200008
2. Brenner RJ, Jackman RJ, Parker SH, Evans WP III, Philpots L, Deutch BM, et al. Percutaneous core needle biopsy of radial scars of the breast: when is excision necessary? AJR Am J Roentgenol. 2002;179(05):1179–1184. Doi: 10.2214/ajr.179.5.1791179
3. Collins LC, Schnitt SJ. Pathology of benign breast disorders. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the breast. 5th ed Philadelphia: Wolters Kluwer Health; 2014:71–88
4. Orr B, Kelley JL III. Benign breast diseases: evaluation and management. Clin Obstet Gynecol. 2016;59(04):710–726. Doi: 10.1097/GRF.0000000000000233
5. Moher D, Liberati A, Tetzlaff J, Altman DGPRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(05):336–341. Doi: 10.1016/j.ijsu.2010.02.007
6. Quinn EM, Dunne E, Flanagan F, Mahon S, Stokes M, Barry MK, et al. Radial scars and complex sclerosing lesions on core needle biopsy of the breast: upgrade rates and long-term outcomes. Breast Cancer Res Treat. 2020;183(03):677–682. Doi: 10.1007/s10549-020-05806-z
7. Woodward SG, Nitzm K, Hookim K, Sevrukov AB, Tsangaris TN, Willis A, et al. Is radial scar on core needle biopsy a risk factor for malignancy? A single-center retrospective review and implications for management. Breast J. 2020;26(10):2011–2014. Doi: 10.1111/tbj.13975
8. Gašišević G, Hertl K, Gačić B, Lamovec J, Žgajnar J. Reducing indications for radial scar surgical excision in Slovenian breast cancer screening program. Ann Diagn Pathol. 2020;45:151438. Doi: 10.1016/j.anndiagpath.2019.151438
9. Bacci J, MacGrogon G, Alran L, Labrot-Hurtevent G. Management of radial scars/complex sclerosing lesions of the breast diagnosed on vacuum-assisted large-core biopsy: is surgery always necessary? Histopathology. 2019;75(06):900–915. Doi: 10.1111/his.13950
10. Mooney KL, Bassett LW, Apple SK. Upgrade rates of high-risk breast lesions diagnosed on core needle biopsy: a single-institution experience and literature review. Mod Pathol. 2016;29(12):1471–1484. Doi: 10.1038/modpathol.2016.127
11. Matrai C, D’Alfonso TM, Pharmar L, Drotman MB, Simmons RM, Shin SJ. Advocating nonsurgical management of patients with small, incidental radial scars at the time of needle core biopsy: a study of 77 cases. Arch Pathol Lab Med. 2015;139(09):1137–1142. Doi: 10.5858/arpa.2014.0550-0A
12. Nassar A, Connors AL, Celik B, Jenkins SM, Smith CY, Hieken TJ. Radial scar/complex sclerosing lesions: a clinicopathologic correlation study from a single institution. Ann Diagn Pathol. 2015;19(01):24–28. Doi: 10.1016/j.anndiagpath.2014.12.003
13. Chou WYY, Veijs DJ, Afr R. Radial scar on image-guided breast biopsy: is surgical excision necessary? Breast Cancer Res Treat. 2018;170(02):313–320. Doi: 10.1007/s10549-018-4741-y
14. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–1388. Doi: 10.1093/jnci/90.18.1371
15. Cuzick J, Statak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, et al; IBIS-II investigators. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet. 2020;395(10218):117–122. Doi: 10.1016/S0140-6736(19)32955-1
16 Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(06):478–488. Doi: 10.1093/jnci/djr027

17 Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12(01):21–29. Doi: 10.1016/S1470-2045(10)70266-7